SCHEMBL7778723

SCHEMBL7778723

O=C(NCCN1CC2CC(c3cccc(O)c3)C2C1)c1ccc(Cl)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.48
HTR1A P08908 3/20 0.47
MAOA P21397 1/20 0.47
MAOB P27338 1/20 0.47
KCNH2 Q12809 1/20 0.47
CD274 Q9NZQ7 1/20 0.47
DRD2 P14416 3/20 0.45
DRD4 P21917 3/20 0.45
DRD3 P35462 2/20 0.45
DRD1 P21728 1/20 0.45
DRD5 P21918 1/20 0.45
TMEM97 Q5BJF2 1/20 0.43
SIGMAR1 Q99720 1/20 0.43
EPHX2 P34913 2/20 0.41
HTR2C P28335 1/20 0.41
PLD1 Q13393 2/20 0.40
PLD2 O14939 1/20 0.40
MAPT P10636 3/20 0.40
CYP1A2 P05177 2/20 0.40
CYP2D6 P10635 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7774081 0.92 ALDH1A1 (0.50) ALDH1A1HTR1AMAOAMAOBKCNH2
SCHEMBL8989722 0.87 DRD4 (0.55) ALDH1A1KCNH2DRD2DRD4MAPT
SCHEMBL7071623 0.82 ALDH1A1 (0.51) ALDH1A1HTR1AMAOAMAOBKCNH2
SCHEMBL8989765 0.82 SIGMAR1 (0.58) ALDH1A1DRD2DRD4DRD3TMEM97
SCHEMBL7817609 0.81 HTR1A (0.46) ALDH1A1HTR1AMAOAMAOBKCNH2
SCHEMBL7078784 0.81 MCHR1 (0.45) ALDH1A1HTR1AMAOAMAOBKCNH2
SCHEMBL8989768 0.81 ALDH1A1 (0.49) ALDH1A1HTR1AMAOAMAOBKCNH2
SCHEMBL7778722 0.81 KDM1A (0.50) CD274SIGMAR1HTR2CPLD1GAA
SCHEMBL7778688 0.80 PLD1 (0.50) HTR1ADRD2DRD3PLD1PLD2
SCHEMBL8135623 0.80 ALDH1A1 (0.55) ALDH1A1HTR1AMAOAMAOBKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1133293-A1 USE OF N-SUBSTITUTED AZABICYCLOALKANE DERIVATIVES FOR TREATING DISEASES OF THE CENTRAL NERVOUS SYSTEM BASF AKTIENGESELLSCHAFT (DE) 2001-09-19 EP disclosed
WO-2000030639-A1 USE OF N-SUBSTITUTED AZABICYCLOALKANE DERIVATIVES FOR TREATING DISEASES OF THE CENTRAL NERVOUS SYSTEM BASF AKTIENGESELLSCHAFT (DE) 2000-06-02 WO disclosed
EP-0646110-B1 N-SUBSTITUTED 3-AZABICYCLO[3.2.0]HEPTANE DERIVATIVES USEFUL AS NEUROLEPTIC AGENTS BASF AG (DE) 1996-10-23 EP disclosed
US-5521209-A N-substituted azabicyclo[3.2.0]heptane derivatives as neuroleptics, the preparation and use thereof BASF AKTIENGESELLSCHAFT (DE) 1996-05-28 US disclosed
EP-0646110-A1 N-SUBSTITUED 3-AZABICYCLO 3.2.0]HEPTANE DERIVATIVES USEFUL AS NEUROLEPTIC AGENTS ETC. BASF AG (DE) 1995-04-05 EP disclosed
WO-1994000431-A1 N-SUBSTITUED 3-AZABICYCLO[3.2.0]HEPTANE DERIVATIVES USEFUL AS NEUROLEPTIC AGENTS ETC. BASF AKTIENGESELLSCHAFT (DE) 1994-01-06 WO disclosed